IVIM & OLINK in Sarcoma
ConditionSoft Tissue Sarcoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-100
SponsorUniversity Health Network, Toronto
About this trial
The hypoxia \> metastasis axis suggests that a DWI-based biomarker of hypoxia incorporating IVIM may be able to predict metastasis in STS patients, ultimately enabling stratification for personalized treatments at the time of diagnostic (MR) imaging, without adding an excessive burden to the patient or clinical workflow (typical DWI/IVIM sequences can be acquired acquired in approximately 5 minutes).
Eligibility criteria
Qualifiers
Age ≥ 18 years
Ability to understand and the willingness to sign a written informed consent document
Grade 2 or 3 soft tissue sarcoma greater than 5 cm in largest dimension
Disqualifiers
Contraindication to MRI scan as per current institutional guidelines (for patients requiring MRI)
Trial design
Treatments tested in this trial
- Radiotherapy
- Surgery
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov